The Twitter Effect on How Oncologists Conduct and Share Research
Many oncologists have long had a love-hate relationship with Twitter. It can help them stay informed of the latest treatment news in a fast-moving field and facilitate dialogue with patients....
View ArticleHow the Coronavirus Pandemic May Affect Cancer Clinical Trials
The health risks posed by SARS-CoV-2 to cancer patients have spurred changes in how cancer clinical trials are being conducted. Some of the alterations introduced by the National Cancer Institute...
View ArticlePatients With CML Continue to Be Prescribed Costly Second-Gen TKIs
Most patients with chronic myelogenous leukemia (CML) are being prescribed costly second-generation tyrosine kinase inhibitors (TKIs), even though generic imatinib has been available since 2016, found...
View ArticleReliability of Laboratory-Developed Tests Called Into Question
The authority of the US Food and Drug Administration (FDA) over laboratory-developed tests (LDTs) has been vague for decades — and an August 2020 announcement from the US Department of Health and...
View ArticleFirst-line Therapy Response vs Switching Treatments in Chronic Myeloid Leukemia
Patients with chronic-phase chronic myeloid leukemia (CP-CML) who respond to first-line tyrosine kinase inhibitor (TKI) treatment may have better responses than those who switch to a second-line...
View ArticleBritish Society for Haematology Guideline Update for the Diagnosis and...
The development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML).1,2 However, despite effectively inducing remission and prolonging survival in...
View ArticleTargeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to...
Since researchers developed the first modern cancer treatments in the 20th century, the number of strategies to treat cancer have exploded, now employing everything from small-molecule drugs,...
View ArticleNCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of...
As part of the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial conducted at more 1000 study sites, researchers have identified actionable alterations in nearly 38% of...
View ArticleDiscontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
The discontinuation of tyrosine kinase inhibitors (TKIs) was demonstrated to be safe, and without apparent limitations on treatment-free remission (TFR) for patients with chronic myeloid leukemia...
View ArticleSTAMP Inhibitor May Be a New Treatment Option in CML
The following article features coverage from the American Society of Hematology 2020 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage. Asciminib, a first-in-class STAMP...
View ArticleAI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML
An artificial intelligence-based model may facilitate selection of optimal frontline tyrosine kinase inhibitor (TKI) therapy for patients with newly diagnosed chronic phase chronic myeloid leukemia...
View ArticleIclusig Approved for Resistant or Intolerant Chronic-Phase CML
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Iclusig® (ponatinib; Takeda) for adults with chronic-phase (CP) chronic myeloid leukemia (CML) with...
View ArticleBiosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Cancer is one of the most expensive diseases to treat and manage, and nearly 20% of patients with cancer and their families spend up to $20,000 each year in total out-of-pocket costs.1 Fortunately,...
View ArticleAnti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical...
The anti-emetic agent metoclopramide blocked CD93 signaling in cell culture and delayed leukemia development in mice, according to data from a preclinical study published in Cell Reports. The results...
View ArticleClik here to view.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in...
A new report from the American Cancer Society (ACS) estimates the cancer diagnoses and deaths expected in 2021 and underscores the disease-specific trends expected to shape a new year in oncology...
View ArticleMolecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor...
Molecular response (MR) in patients with chronic myeloid leukemia (CML) who were not eligible for treatment discontinuation was maintained with a long-term tyrosine kinase inhibitor (TKI) regimen of 1...
View ArticleCase Study Shows Potential Protective Effect of TKI Therapy for Chronic...
The use of tyrosine kinase inhibitor (TKI) therapy may provide a degree of protection against COVID-19 in patients with chronic myeloid leukemia (CML). These findings are suggested by in a case report...
View ArticleBCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With...
Baseline kinetics of breakpoint cluster region (BCR)-ABL proto-oncogene 1 (ABL1) and decline over time in patients with chronic myeloid leukemia (CML) was associated with long-term remission status....
View ArticleDasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia
Dasatinib and nilotinib are effective second-line therapies for patients with chronic phase chronic myeloid leukemia (CP-CML) based on real-world data published in Annals of Hematology. More than 20%...
View ArticleHow Intermittent Fasting Affects Patients Receiving Tyrosine Kinase...
A lack of research on the effects of intermittent fasting on patients undergoing treatment for chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) inspired a team of researchers in...
View Article